Merck raises guidance as Keytruda sales jump 20% in Q1 [Seeking Alpha]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Seeking Alpha
full-year outlook amid ~20% YoY growth in sales for its blockbuster cancer medicine Keytruda. Merck's ( MRK ) Q1 sales reached $15.8B, with ~9% YoY growth on a reported basis, beating Street forecasts by as much as $600M, as the anti-PD-1 immunotherapy generated $6.9B in sales during the quarter, exceeding $6.7B in the Bloomberg consensus. Meanwhile, sales from MRK's animal health business and its human papillomavirus vaccine, Gardasil, also topped expectations, adding $1.5B and $2.3B to the topline with ~1% YoY and ~14% YoY growth, respectively. “We drove strong growth across key therapeutic areas and executed strategic business development,” CEO Robert Davis remarked, highlighting the ongoing launch of Winrevair, a recently approved lung disease therapy Merck ( MRK ) acquired with its $11.7B buyout of Acceleron in 2021. “We have important opportunities ahead of us across all areas of our business, and we are highly focused on realizing them,” Davis added. Meanwhile, MRK's
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Here's Why Merck (MRK) is a Strong Momentum Stock [Yahoo! Finance]Yahoo! Finance
- Generic Sterile Injectable Market Size to Worth USD 108.54 Bn by 2033 [Yahoo! Finance]Yahoo! Finance
- 4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration [Yahoo! Finance]Yahoo! Finance
- Merck reports data from Phase III gastric cancer treatment trial [Yahoo! Finance]Yahoo! Finance
- The top pharmaceutical companies by R&D expenditure [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 4/25/24 - Beat
MRK
Sec Filings
- 5/3/24 - Form 10-Q
- 5/2/24 - Form 4
- 5/2/24 - Form 4
- MRK's page on the SEC website